| scholarly article | Q13442814 |
| P50 | author | Duxin Sun | Q95935419 |
| Xianhua Cao | Q114413498 | ||
| Ho-chul Shin | Q42630718 | ||
| Christopher P. Landowski | Q44684419 | ||
| Gordon L. Amidon | Q56166547 | ||
| P2093 | author name string | Yanqiang Zhong | |
| Lawrence X Yu | |||
| Lanyan Fang | |||
| Hans Lennernas | |||
| Seth T Gibbs | |||
| Heather A Miller | |||
| P2860 | cites work | cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3)1 | Q24314274 |
| Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine | Q28140655 | ||
| CYP3A gene expression in human gut epithelium | Q28236591 | ||
| Clinical Pharmacokinetics of N-acetylprocainamide | Q28262289 | ||
| A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability | Q28293773 | ||
| Evaluation of rat intestinal absorption data and correlation with human intestinal absorption | Q30782163 | ||
| In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome | Q30908306 | ||
| Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach | Q31962885 | ||
| Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. | Q33183493 | ||
| Is the role of the small intestine in first-pass metabolism overemphasized? | Q33650100 | ||
| Comparison between permeability coefficients in rat and human jejunum | Q34063545 | ||
| Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats | Q34067981 | ||
| Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases | Q34172660 | ||
| Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine | Q34255245 | ||
| First-pass elimination. Basic concepts and clinical consequences | Q34257205 | ||
| Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents | Q34339828 | ||
| The oligopeptide transporter (Pept-1) in human intestine: biology and function | Q34431100 | ||
| Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma | Q34656950 | ||
| Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes | Q35608569 | ||
| The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers | Q35802614 | ||
| The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans | Q36053628 | ||
| Clinical pharmacokinetics of ketoprofen and its enantiomers | Q37950598 | ||
| Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension | Q38679740 | ||
| Clinical pharmacokinetics of the salicylates | Q39820095 | ||
| Clinical pharmacokinetics of the antituberculosis drugs | Q40196353 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| Levonorgestrel. Clinical pharmacokinetics | Q40530282 | ||
| Characterization of human small intestinal cytochromes P-450. | Q40945563 | ||
| Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption | Q41581115 | ||
| Human Intestinal Permeability | Q41741549 | ||
| Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. | Q41809930 | ||
| ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2 | Q41945509 | ||
| Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation | Q42108944 | ||
| The metabolism and kinetics of doxazosin in man, mouse, rat and dog. | Q43181893 | ||
| Human jejunal permeability of two polar drugs: cimetidine and ranitidine | Q43689063 | ||
| Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter | Q43768018 | ||
| Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. | Q43823771 | ||
| Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. | Q43893557 | ||
| Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats | Q43938200 | ||
| Comparison of oral absorption and bioavailablity of drugs between monkey and human | Q44074776 | ||
| Gene Expression in the Human Intestine and Correlation with Oral Valacyclovir Pharmacokinetic Parameters | Q44443325 | ||
| A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method | Q45080959 | ||
| Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract | Q45137071 | ||
| Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. | Q45164840 | ||
| Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag | Q47268173 | ||
| Chronic nifedipine dosing enhances cephalexin bioavailability and intestinal absorption in conscious rats. | Q51375057 | ||
| Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism | Q51530623 | ||
| Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism | Q51848217 | ||
| Pharmacokinetics of methyldopa in man | Q67486216 | ||
| Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man | Q67591105 | ||
| Bioavailability study of furosemide prodrugs in rats | Q67829865 | ||
| Predicting fraction dose absorbed in humans using a macroscopic mass balance approach | Q68019654 | ||
| Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues | Q68761368 | ||
| Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril | Q69364366 | ||
| Bioavailability of codeine preparations in the rat | Q69587846 | ||
| Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine | Q69967629 | ||
| Buccal and oral bioavailability of nalbuphine in rats | Q70033036 | ||
| Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet | Q70197771 | ||
| Intestinal absorption of amino acid derivatives: importance of the free alpha-amino group | Q70517953 | ||
| Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys | Q70564074 | ||
| The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey | Q71002118 | ||
| Immuno-localization of H+/peptide cotransporter in rat digestive tract | Q71016717 | ||
| Bioavailability of indomethacin calcium and magnesium, and effect of the salts on drug metabolizing enzyme activities in rats | Q71186964 | ||
| Interaction of tri-O-methyl-beta-cyclodextrin with drugs. II. Enhanced bioavailability of ketoprofen in rats when administered with tri-O-methyl-beta-cyclodextrin | Q71195379 | ||
| The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum | Q71252169 | ||
| Isosorbide 5-mononitrate kinetics | Q71322877 | ||
| The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats | Q72143720 | ||
| Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences | Q72552909 | ||
| The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum | Q72579170 | ||
| Bioavailability of N-acetylprocainamide from mixed diet in rats | Q72637538 | ||
| Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat | Q73121137 | ||
| Jejunal permeability: a comparison between the ussing chamber technique and the single-pass perfusion in humans | Q73371188 | ||
| Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model | Q73484149 | ||
| Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion | Q73779038 | ||
| Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine | Q73944331 | ||
| Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats | Q74131049 | ||
| Jejunal absorption and metabolism of R/S-verapamil in humans | Q74731555 | ||
| STUDIES ON THE ABSORPTION, METABOLISM AND EXCRETION OF METHYLDOPA AND OTHER CATECHOLS AND THEIR INFLUENCE ON AMINO ACID TRANSPORT IN RATS | Q76958530 | ||
| Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs | Q78498262 | ||
| Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver | Q79076956 | ||
| P433 | issue | 8 | |
| P921 | main subject | bioavailability | Q461809 |
| P304 | page(s) | 1675-1686 | |
| P577 | publication date | 2006-08-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model | |
| P478 | volume | 23 |
| Q51694483 | A Minireview: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability |
| Q37033782 | A novel culture system for adult porcine intestinal crypts |
| Q57570927 | Alginate/Chitosan Nanoparticles are Effective for Oral Insulin Delivery |
| Q36148717 | An In Silico Knockout Model for Gastrointestinal Absorption Using a Systems Pharmacology Approach - Development and Application for Ketones. |
| Q91895343 | Animal to human translation: a systematic scoping review of reported concordance rates |
| Q42744069 | Animal versus human oral drug bioavailability: do they correlate? |
| Q46415850 | Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon |
| Q35888391 | Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation |
| Q43171588 | Assessment of intestinal absorption of total flavones of Hippophae rhamnoides L. in rat using in situ absorption models |
| Q37800414 | Biomagnetic methods: technologies applied to pharmaceutical research |
| Q93024486 | Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective |
| Q85347525 | Chemical analysis and anti-inflammatory comparison of the cell culture of Glycyrrhiza with its field cultivated variety |
| Q47232155 | Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat-Biophysical Model and Predictions Based on Caco-2. |
| Q34128770 | Coexistence of passive and carrier-mediated processes in drug transport |
| Q37190801 | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin |
| Q45263024 | Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method |
| Q57103645 | Comparison of intestinal permeability and p-glycoprotein effects on the intestinal absorption of enantiomers of 2-(2-hydroxypropanamido) benzoic acid in rats |
| Q83973097 | Comparison of the intestinal absorption and bioavailability of γ‐tocotrienol and α‐tocopherol: in vitro, in situ and in vivo studies |
| Q39205354 | Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification |
| Q43433452 | Determination of lamivudine and zidovudine permeability using a different ex vivo method in Franz cells |
| Q64067193 | Drug Transport across Porcine Intestine Using an Ussing Chamber System: Regional Differences and the Effect of P-Glycoprotein and CYP3A4 Activity on Drug Absorption |
| Q37514340 | Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior |
| Q39433291 | Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: Possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by baicalein |
| Q39419233 | Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine |
| Q53848245 | Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin |
| Q39434669 | Effects of myricetin on the bioavailability of carvedilol in rats |
| Q83548877 | Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in Rats: Possible role of CYP3A4 and P-glycoprotein inhibition by myricetin |
| Q83730580 | Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats |
| Q39547723 | Effects of quercetin on the bioavailability of doxorubicin in rats: Role of CYP3A4 and P-gp inhibition by quercetin |
| Q37729496 | Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats |
| Q34732480 | Efffect of the ABCC3 –211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention |
| Q88165727 | Elucidation of the Intestinal Absorption of para-Aminobenzoic Acid, a Marker for Dietary Intake |
| Q39574444 | Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. |
| Q89209158 | Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice |
| Q39895437 | Fasting increases tobramycin oral absorption in mice |
| Q40667203 | Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates |
| Q37942267 | Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration |
| Q37742846 | Functional cell models of the gut and their applications in food microbiology--a review |
| Q37600381 | Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination |
| Q42440768 | Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation |
| Q64108609 | Impact of Subacute Exposure to T-2 Toxin and Zearalenone on the Pharmacokinetics of Midazolam as CYP3A Probe Drug in a Porcine Animal Model: A Pilot Study |
| Q36909306 | Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans |
| Q46948657 | Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained release delivery systems of antimicrobials |
| Q36835817 | Improving metabolic stability of cancer chemoprotective polyphenols |
| Q26800893 | Interactions between CYP3A4 and Dietary Polyphenols |
| Q86446390 | Intestinal and hepatic first-pass extraction of the 11β-HSD1 inhibitor AMG 221 in rats with chronic vascular catheters |
| Q36985043 | Intestinal permeability and its relevance for absorption and elimination |
| Q38051447 | Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug–drug interactions |
| Q86070985 | Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats |
| Q84224933 | Magnetic Active Agent Release System (MAARS): Evaluation of a new way for a reproducible, externally controlled drug release into the small intestine |
| Q37207759 | Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters |
| Q33432960 | Mechanistic approaches to predicting oral drug absorption |
| Q37671826 | Mitigating permeability-mediated risks in drug discovery |
| Q34197425 | Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme |
| Q37194304 | Modeling kinetics of subcellular disposition of chemicals. |
| Q51042522 | Modern prodrug design for targeted oral drug delivery. |
| Q36050847 | Mucosal and blood-brain barrier transport kinetics of the plant N-alkylamide spilanthol using in vitro and in vivo models. |
| Q59058460 | Nanocrystallization of the Pharmaceutically Active Agent Genipin by an Emulsion Solvent Evaporation Method |
| Q38731211 | Non-animal approaches for toxicokinetics in risk evaluations of food chemicals |
| Q36985094 | On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development |
| Q45400881 | Ontogeny of CYP3A and P-glycoprotein in the liver and the small intestine of the Göttingen minipig: an immunohistochemical evaluation |
| Q27023585 | Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? |
| Q39038877 | Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions |
| Q33867814 | PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach |
| Q44432013 | Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol |
| Q57137963 | Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration |
| Q45209671 | Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach |
| Q39805145 | Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance |
| Q36885247 | Prediction of human pharmacokinetics--gastrointestinal absorption |
| Q34583462 | Prediction of human pharmacokinetics--gut-wall metabolism |
| Q34833273 | Predictive approaches to increase absorption of compounds during lead optimisation |
| Q43499119 | Presystemic Metabolism of AZ’0908, A Novel mPGES-1 Inhibitor: An In Vitro and In Vivo Cross-Species Comparison |
| Q35026563 | Prevention strategies for antimicrobial resistance: a systematic review of the literature |
| Q38177366 | Pros and cons of methods used for the prediction of oral drug absorption. |
| Q35292187 | Qian Yang Yu Yin Granule-containing serum inhibits angiotensin II-induced proliferation, reactive oxygen species production, and inflammation in human mesangial cells via an NADPH oxidase 4-dependent pathway |
| Q47851974 | Quercetin nanoparticles alter pharmacokinetics of bromocriptine, reflecting its enhanced inhibitory action on liver and intestinal CYP 3A enzymes in rats |
| Q46977325 | Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human |
| Q90393324 | Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat |
| Q46137927 | Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance |
| Q43257599 | Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice |
| Q51443735 | Sex differences in pharmacokinetics of cilostazol in rats |
| Q43516241 | Single-pass intestinal perfusion to establish the intestinal permeability of model drugs in mouse |
| Q37325992 | Systematic analysis of the polyphenol metabolome using the Phenol-Explorer database |
| Q38019048 | Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. |
| Q38791121 | The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model. |
| Q39133310 | The Contributions of Human Mini-Intestines to the Study of Intestinal Physiology and Pathophysiology |
| Q42131253 | The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship |
| Q97093738 | The past, present and future of intestinal in vitro cell systems for drug absorption studies |
| Q39809409 | The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans |
| Q37537018 | The role of transporters in the pharmacokinetics of orally administered drugs |
| Q36634723 | The use of BDDCS in classifying the permeability of marketed drugs |
| Q30670381 | The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. |
| Q48308026 | The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine. |
| Q30388503 | Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals |
| Q37739302 | Use of in vivo animal models to assess pharmacokinetic drug-drug interactions |
| Q38239571 | Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices |
Search more.